Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseNHL, B-cell type, primary Lymphoma of the central nervous system SubgroupICD10C83.3MeSHSequenceFreiburg CNS-NHL StudyChemotherapyChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaNo. Substances3 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPrednisoloneNo. Substances9Protocol classificationTherapy classificationcurrent standardIntensityhigh doseTherapy indicationFirst lineTherapy phaseautologous stem cell transplantationTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Increase AminotransferasesInfectionsLeukopeniaMucositisPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorIllerhaus GDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 JahreOriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollProtocols in Revision 1 protocol foundRituximab 375 / Carmustine 400 / Thiotepa 5, primary central nervous system Lymphoma, conditioning, cycle 5 (PID1883 V1.0)
